June 26, 2020 / 1:13 PM / 6 days ago

BRIEF-Citius Receives FDA Response On Pre-IND Application For Acute Respiratory Distress Syndrome Treatment In Patients With Covid-19

June 26 (Reuters) - Citius Pharmaceuticals Inc:

* CITIUS RECEIVES FDA RESPONSE ON PRE-INVESTIGATIONAL NEW DRUG (PIND) APPLICATION FOR ITS INDUCED MESENCHYMAL STEM CELLS (IMSCS) TO TREAT ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS WITH COVID-19

* CITIUS PHARMACEUTICALS INC - INTENDS TO SUBMIT AN IND APPLICATION FOR ITS IMSC THERAPY FOR PATIENTS WITH ARDS ASSOCIATED WITH COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below